Skip to main content

Gastrointestinal Cancer Specialty Channel

Gastrointestinal Cancer
Specialty Channel
FDA Approval
10/18/2024
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the...
10/18/2024
Oncology
Conference Coverage
09/14/2024
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Findings from the phase 3...
09/14/2024
Oncology
News
08/09/2024
According to results from the phase 2 NIFE study, nanoliposomal irinotecan with fluorouracil and leucovorin in the first-line setting demonstrated efficacy and safety among patients with advanced, unresectable cholangiocarcinoma.
According to results from the phase 2 NIFE study, nanoliposomal irinotecan with fluorouracil and leucovorin in the first-line setting demonstrated efficacy and safety among patients with advanced, unresectable cholangiocarcinoma.
According to results from the...
08/09/2024
Oncology
News
05/23/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the...
05/23/2024
Oncology
News
04/24/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the...
04/24/2024
Oncology
News
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
Conference Coverage
01/19/2024
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis...
01/19/2024
Oncology
Conference Coverage
01/19/2024
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology
Conference Coverage
01/18/2024
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the...
01/18/2024
Oncology
News
10/16/2023
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial,...
10/16/2023
Oncology
News
10/13/2023
According to results from a phase 2 basket study, tucatinib plus trastuzumab demonstrated antitumor activity and was well-tolerated among patients with previously treated HER2-positive metastatic biliary tract cancer.
According to results from a phase 2 basket study, tucatinib plus trastuzumab demonstrated antitumor activity and was well-tolerated among patients with previously treated HER2-positive metastatic biliary tract cancer.
According to results from a...
10/13/2023
Oncology

News

FDA Approval
10/18/2024
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the...
10/18/2024
Oncology
Conference Coverage
09/14/2024
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Findings from the phase 3...
09/14/2024
Oncology
News
08/09/2024
According to results from the phase 2 NIFE study, nanoliposomal irinotecan with fluorouracil and leucovorin in the first-line setting demonstrated efficacy and safety among patients with advanced, unresectable cholangiocarcinoma.
According to results from the phase 2 NIFE study, nanoliposomal irinotecan with fluorouracil and leucovorin in the first-line setting demonstrated efficacy and safety among patients with advanced, unresectable cholangiocarcinoma.
According to results from the...
08/09/2024
Oncology
News
05/23/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the...
05/23/2024
Oncology
News
04/24/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the...
04/24/2024
Oncology
News
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
Conference Coverage
01/19/2024
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis...
01/19/2024
Oncology
Conference Coverage
01/19/2024
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology
Conference Coverage
01/18/2024
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the...
01/18/2024
Oncology
News
10/16/2023
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial,...
10/16/2023
Oncology

Interactive Features

Quiz
10/17/2022
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy...
10/17/2022
Oncology
Test Your Knowledge
09/08/2021
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon...
09/08/2021
Oncology
Quiz
08/09/2021
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination...
08/09/2021
Oncology
Test Your Knowledge
01/28/2021
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has...
01/28/2021
Oncology
Test Your Knowledge
08/28/2020
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did...
08/28/2020
Oncology
Test Your Knowledge
08/21/2020
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with...
08/21/2020
Oncology
Test Your Knowledge
08/21/2020
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and...
08/21/2020
Oncology
Test Your Knowledge
07/31/2020
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival...
07/31/2020
Oncology
Test Your Knowledge
06/22/2020
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma...
06/22/2020
Oncology
Test Your Knowledge
06/04/2020
True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?
True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?
True or False: Pembrolizumab...
06/04/2020
Oncology